Literature DB >> 31570348

Antifungals in a case of basidiobolomycosis: role and limitations.

Anjum Saeed1, Asaad M Assiri2, Ishfaq A Bukhari3, Rasha Assiri4.   

Abstract

A 10-year-old Saudi boy was diagnosed to have basidiobolomycosis after a stormy course of his ailment. Therapy was initiated with intravenous antifungal, voriconazole, which was well tolerated for 6 weeks except for local excoriation at the site of ileostomy. He developed drug-induced hepatitis on oral voriconazole, therefore, switched to oral itraconazole following which he experienced severe chest pain. Alternatively, co-trimoxazole (bactrim) an antibacterial with antifungal activity was prescribed but he had the intolerance to it as well. Unfortunately, posaconazole as an alternative antifungal was not available in our centre. We report here a Saudi boy who developed an intolerance to most common antifungals used clinically 6 weeks after the therapy was initiated. © BMJ Publishing Group Limited 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  paediatrics; unwanted effects/adverse reactions

Mesh:

Substances:

Year:  2019        PMID: 31570348     DOI: 10.1136/bcr-2019-230206

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  3 in total

1.  Challenge of Ziehl-Neelsen stain for Basidiobolomycosis diagnosis in Indonesia: A unique case report.

Authors:  Metta Octora; Arthur Pohan Kawilarang; Pepy Dwi Endraswari
Journal:  Ann Med Surg (Lond)       Date:  2022-01-25

2.  Visceral Basidiobolomycosis Causing Bowel Ischemia.

Authors:  Waleed Mahmoud; Mahwish Khawar; Mahir Petkar; Thasneem Odaippurath; Mohamed Kurer
Journal:  Cureus       Date:  2022-06-21

3.  Invasive Basidiobolomycosis Presenting as Retroperitoneal Fibrosis: A Case Report.

Authors:  Abdulmalek Alsharidah; Yahya Mahli; Nayef Alshabyli; Mohammed Alsuhaibani
Journal:  Int J Environ Res Public Health       Date:  2020-01-15       Impact factor: 3.390

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.